DOUGLAS WATSON: Open Payments
NPI 1770211658 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,922 in 102 payments from 14 companies in 2025. Trend: 2023 $986 · 2024 $1,906 · 2025 $1,922
Food & beverage: $1,922
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $521 |
| Axsome Therapeutics, Inc. | 9 | $322 |
| Alkermes, Inc. | 19 | $238 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $231 |
| Teva Pharmaceuticals USA, Inc. | 3 | $159 |
| Vanda Pharmaceuticals Inc. | 8 | $149 |
| Otsuka America Pharmaceutical, Inc. | 6 | $102 |
| Lundbeck LLC | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
Products named: VRAYLAR, Auvelity, CAPLYTA, ARISTADA, UZEDY, HETLIOZ, REXULTI, LYBALVI.
Industry payments across IN — which companies pay providers there.
